Patents by Inventor Patrick Finn

Patrick Finn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10464962
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 5, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • Patent number: 10328218
    Abstract: A nebulizer system includes a body having a fluid chamber and an aerosol chamber, and a vibrator assembly positioned at an interface between the fluid chamber and the aerosol chamber. The vibrator assembly may include a diaphragm, having a fluid side and an aerosol side, defining a plurality of perforations between the fluid side and the aerosol side, and one or more vibrator elements operatively associated with the diaphragm to vibrate the diaphragm to produce aerosolized medicament projected into the aerosol chamber from the plurality of perforations. Each perforation of the plurality of perforations projects the aerosolized medicament along a respective projection path relative to a plane defined by the aerosol side of the perforation, the one or more vibrator elements or the diaphragm support substrate further being configured to angularly displace the aerosol side of the diaphragm to sweep the direction of at least one projection path.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: June 25, 2019
    Assignee: ENGINEERED MEDICAL SYSTEMS, INC.
    Inventors: George Ashford Reed, Jeffrey John Quinn, Brad Hayden Quinn, Patrick Finn Boileau
  • Publication number: 20190078084
    Abstract: The present disclosure relates to methods and kits for DNA library construction, particularly for consistent and reproducible DNA sequencing.
    Type: Application
    Filed: April 4, 2018
    Publication date: March 14, 2019
    Applicant: ArcherDX, Inc.
    Inventors: Patrick Finn, Greg Patton, Hongbo Liu
  • Publication number: 20190062416
    Abstract: A method of treating primary focal segmental glomerulosclerosis in a patient having an APOL1 variant, comprising intravenously administering a TGF? antagonist to the patient.
    Type: Application
    Filed: June 17, 2016
    Publication date: February 28, 2019
    Applicant: GENZYME CORPORATION
    Inventors: Steven R. Ledbetter, Sara Engstrand, Patrick Finn, Julie Lin, Robert John Pomponio
  • Publication number: 20180244763
    Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
    Type: Application
    Filed: January 19, 2018
    Publication date: August 30, 2018
    Applicant: SANOFI
    Inventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu
  • Patent number: 9861779
    Abstract: An improved oscillating positive expiratory pressure (“OPEP”) device, for respiratory therapy having a self sterilizing flow valve capable of insertion into the curved OPEP body without tools or aids. The flow valve is also tear resistant and incorporates a flared reinforced proximal end. To maximize the benefit to patients, the adjustable therapy selector is constrained from withdrawal and is dimensioned to accept commercially available, standardized respiratory fittings adaptors, mouthpieces and “Tees” that are capable of connection to multiple respiratory therapy devices or medicated aerosol delivery units. The aesthetics have been altered by the addition of an arced handle.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: January 9, 2018
    Inventors: George Ashford Reed, Patrick Finn Boileau
  • Publication number: 20180002365
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 4, 2018
    Inventors: Luis Z. AVILA, Clark Q. PAN, Patrick FINN, John HARRAHY, Qun ZHOU, Yunxiang ZHU, Paul A. KONOWICZ, Duncan E. PATERSON, Andreas PEER, Joseph P. KUTZKO, Michael R. REARDON, James E. STEFANO, Xiaoyang ZHENG, Robert J. MILLER, Lauren YOUNG
  • Publication number: 20170361056
    Abstract: An improved oscillating positive expiratory pressure (“OPEP”) device, for respiratory therapy having a self sterilizing flow valve capable of insertion into the curved OPEP body without tools or aids. The flow valve is also tear resistant and incorporates a flared reinforced proximal end. To maximize the benefit to patients, the adjustable therapy selector is constrained from withdrawal and is dimensioned to accept commercially available, standardized respiratory fittings adaptors, mouthpieces and “Tees” that are capable of connection to multiple respiratory therapy devices or medicated aerosol delivery units. The aesthetics have been altered by the addition of an arced handle.
    Type: Application
    Filed: June 21, 2016
    Publication date: December 21, 2017
    Inventors: George Ashford Reed, Patrick Finn Boileau
  • Publication number: 20170106155
    Abstract: A nebulizer system includes a body having a fluid chamber and an aerosol chamber, and a vibrator assembly positioned at an interface between the fluid chamber and the aerosol chamber. The vibrator assembly may include a diaphragm, having a fluid side and an aerosol side, defining a plurality of perforations between the fluid side and the aerosol side, and one or more vibrator elements operatively associated with the diaphragm to vibrate the diaphragm to produce aerosolized medicament projected into the aerosol chamber from the plurality of perforations. Each perforation of the plurality of perforations projects the aerosolized medicament along a respective projection path relative to a plane defined by the aerosol side of the perforation, the one or more vibrator elements or the diaphragm support substrate further being configured to angularly displace the aerosol side of the diaphragm to sweep the direction of at least one projection path.
    Type: Application
    Filed: May 5, 2016
    Publication date: April 20, 2017
    Inventors: George Ashford Reed, Jeffrey John Quinn, Brad Hayden Quinn, Patrick Finn Boileau
  • Patent number: 9493498
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: November 15, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • Patent number: 9352108
    Abstract: A nebulizer system includes a body having a fluid chamber and an aerosol chamber, and a vibrator assembly positioned at an interface between the fluid chamber and the aerosol chamber. The vibrator assembly may include a diaphragm, having a fluid side and an aerosol side, defining a plurality of perforations between the fluid side and the aerosol side, and one or more vibrator elements operatively associated with the diaphragm to vibrate the diaphragm to produce aerosolized medicament projected into the aerosol chamber from the plurality of perforations. Each perforation of the plurality of perforations projects the aerosolized medicament along a respective projection path substantially normal to a plane defined by the aerosol side of the perforation, the one or more vibrator elements further being configured to angularly displace the aerosol side of the diaphragm to sweep the direction of at least one projection path.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: May 31, 2016
    Inventors: George Ashford Reed, Jeffrey John Quinn, Brad Hayden Quinn, Patrick Finn Boileau
  • Publication number: 20160063449
    Abstract: A method is provided for scheduling a meeting. The method includes receiving a request from an organizer to schedule a meeting, executing a constraint satisfaction algorithm to determine at least one meeting data set comprising a value for at least one variable in a set of variables. The meeting data set defines at least one of a proposed time, room or participants for the meeting. Executing the constraint satisfaction algorithm involves performing a backtracking search within a solution domain to determine the meeting data set for the set of variables that satisfies a set of meeting constraints. If no meeting data set is determined, the set of variables and the solution domain can be revised. A next backtracking search can be performed to determine the meeting data set for the revised set of variables in the revised solution domain that satisfies one or more of the meeting constraints.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 3, 2016
    Inventors: Colin Duggan, Patrick Finn, James Wagstaff, Kevin Burke
  • Patent number: 9266834
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: February 23, 2016
    Assignees: Janssen Pharmaceuticals, Inc., Addex Pharma SA
    Inventors: Hassan Julien Imogai, Jose Maria Cid-Nunez, Jose Ignacio Andres-Gil, Andres Avelino Trabanco-Suarez, Julen Oyarzabal Santamarina, Frank Matthias Dautzenberg, Gregor James MacDonald, Shriley Elizabeth Pullan, Robert Johannes Lutjens, Guillaume Albert Jacques Duvey, Vanthea Nhem, Terry Patrick Finn, Gagik Melikyan
  • Publication number: 20150336930
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Application
    Filed: August 4, 2015
    Publication date: November 26, 2015
    Inventors: JOSE MARIA CID-NUNEZ, ANDRES AVELINO TRABANCO-SUAREZ, GREGOR JAMES MACDONALD, GUILLAUME ALBERT JACQUES DUVEY, ROBERT JOHANNES LÜTJENS, TERRY PATRICK FINN
  • Publication number: 20150291953
    Abstract: The present disclosure relates to methods and kits for DNA library construction, particularly for consistent and reproducible DNA sequencing.
    Type: Application
    Filed: November 4, 2013
    Publication date: October 15, 2015
    Inventors: Patrick Finn, Greg Patton, Hongbo Liu
  • Patent number: 9132122
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: September 15, 2015
    Assignees: Janssen Pharmaceuticals, Inc., Addex Pharma SA
    Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Robert Johannes Lütjens, Terry Patrick Finn
  • Patent number: 9114138
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: August 25, 2015
    Assignees: Janssen Pharmaceuticals, Inc., Addex Pharma SA
    Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Robert Johannes Lutjens, Terry Patrick Finn
  • Publication number: 20150175643
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Application
    Filed: July 29, 2014
    Publication date: June 25, 2015
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • Publication number: 20140315903
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: HASSAN JULIEN IMOGAI, JOSE MARIA CID-NUNEZ, JOSE IGNACIO ANDRES-GIL, ANDRES AVELINO TRABANCO-SUAREZ, JULEN OYARZABAL SANTAMARINA, FRANK MATTHIAS DAUTZENBERG, GREGOR JAMES MACDONALD, SHRILEY ELIZABETH PULLAN, ROBERT JOHANNES LUTJENS, GUILLAUME ALBERT JACQUES DUVEY, VANTHEA NHEM, TERRY PATRICK FINN, GAGIK MELIKYAN
  • Patent number: 8841323
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: September 23, 2014
    Assignees: Janssen Pharmaceuticals, Inc., Addex Pharma S.A.
    Inventors: Jose Maria Cid-Nunez, Jose Ignacio Andres-Gil, Andres Avelino Trabanco-Suarez, Julen Oyarzabal Santamarina, Frank Matthias Dautzenberg, Gregor James MacDonald, Shirley Elizabeth Pullan, Robert Johannes Lutjens, Guillaume Albert Jacques Duvey, Vanthea Nhem, Terry Patrick Finn, Gagik Melikyan, Vincent Mutel